OCUL
OCULAR THERAPEUTIX, INC
NASDAQ · Healthcare · Biotechnology · US
$6.40
+1.82%Year over year
Reported trailing growth
- Revenue
- -8.1%
- EBITDA
- -41.9%
- EBIT
- -37.6%
- EPS
- -10.9%
- Free cash flow
- -42.2%
- Operating cash flow
- -35.4%
Forward estimates
Based on analyst estimates
- Revenue
- +38.4%
- EBITDA
- -12.7%
- EPS
- -6.2%
Three-year CAGR
- Revenue
- +0.2%
- EBITDA
- -41.8%
- EBIT
- -57.2%
- Net income
- -37.4%
- EPS
- -16.4%
- Free cash flow
- -59.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026